Oxycodone - Revision history

MDElliottMD: parser-claude: Oxycodone MedTemplate refill, Top 300 stub upgrade

2026-05-23T06:37:36Z

parser-claude: Oxycodone MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 06:37, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Oxycodone		\| generic = Oxycodone (hydrochloride)
	\| brand = OxyContin		\| brand = OxyContin (ER), Roxicodone (IR), Oxaydo (IR abuse-deterrent), Xtampza ER (abuse-deterrent ER)
	\| structure =		\| structure =
	\| classes = Opioid, Analgesic		\| classes = [[:Category:Opioid analgesics\|Opioid analgesic (semi-synthetic)]], [[:Category:Schedule II controlled substances\|Schedule II controlled substance]], [[:Category:Analgesics\|Analgesic]]
	\| ~~mechanism~~ = Mu-opioid ~~receptor agonist~~		\| uses = <vote slug="moderate-severe-acute-pain-use">Moderate to severe acute pain (FDA)</vote>, <vote slug="post-surgical-pain-use">Postoperative pain (FDA)</vote>, <vote slug="cancer-pain-use">Cancer pain (FDA)</vote>, <vote slug="severe-chronic-pain-use">Severe chronic pain unresponsive to non-opioid alternatives (FDA, with the CDC opioid prescribing guidance constraints)</vote>
	\| ~~uses~~ =		\| starting_dose = IR opioid-naive: 5-10 mg PO every 4-6 hours as needed. ER opioid-naive: '''10 mg PO every 12 hours (lowest available)'''; titrate slowly to clinical effect
	\| ~~starting_dose~~ =		\| preparations = IR tablets 5, 7.5, 10, 15, 20, 30 mg; IR oral solution 5 mg/5 mL; concentrated solution 20 mg/mL; OxyContin ER tablets 10, 15, 20, 30, 40, 60, 80 mg; Xtampza ER capsules
	\| ~~preparations~~ =		\| fda_max = No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals
	\| ~~fda_max~~ =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = 10-30 minutes (IR)
	\| duration =		\| duration = 4-6 hours (IR); 12 hours (ER)
	\| halflife =		\| halflife = 3-5 hours (IR); 4.5 hours (ER)<ref name="oxycontin-label">FDA Prescribing Information, OxyContin (oxycodone hydrochloride extended-release), Purdue Pharma, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022272s033lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ~60-87% (oral; high and more consistent than codeine or hydrocodone, making efficacy less CYP2D6-genotype-dependent)<ref name="oxycontin-label" />
	~~\| pregnancy~~ =		\| pregnancy = Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.{{citation needed}}
	~~\| legal~~ =		\| legal = [[USLegal:Schedule II\|Schedule II controlled substance]] in US<ref name="oxycontin-label" />
	\| ~~intro =~~		\| mechanism = <vote slug="oxycodone-mech-claim">Semi-synthetic μ-opioid receptor agonist, intermediate in potency between hydrocodone and morphine. Metabolized via CYP3A4 N-demethylation to noroxycodone (largely inactive) and via CYP2D6 O-demethylation to oxymorphone (active, more potent at μ). Unlike codeine and hydrocodone, oxycodone itself is largely the analgesic agent, so efficacy is less CYP2D6-genotype-dependent than for codeine.</vote> CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice) substantially raise plasma exposure. OxyContin's 2010 reformulation introduced an abuse-deterrent matrix that resists crushing and dissolution, a major harm-reduction intervention. CPIC provides CYP2D6 genotype-guided opioid selection guidance<ref name="cpic-opioid-cyp2d6">CPIC Guideline for CYP2D6, OPRM1, and COMT and Opioid Use, 2021. https://cpicpgx.org/guidelines/cpic-guideline-for-codeine-and-cyp2d6/</ref>.
	~~\| pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	\| ~~indications~~ =
	\| ~~dosing~~ =
	\| ~~effects~~ =
	~~\| interactions = <pharmaInteractions~~/>
	\| ~~pregnancy_details =~~
	~~\| monitoring~~ =
	~~\| counseling~~ =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

			== References ==
			<references />

	[[Category:~~Opioids~~]]		[[Category:Opioid analgesics]]
	[[Category:~~Semisynthetic opioids~~]]		[[Category:Schedule II controlled substances]]
	[[Category:Analgesics]]		[[Category:Analgesics]]
	~~[[Category:Mu-Opioid Receptor Agonists]]~~

MDElliottMD: Comprehensive categorization: +Mu-Opioid Receptor Agonists

2026-05-15T18:42:14Z

Comprehensive categorization: +Mu-Opioid Receptor Agonists

← Older revision		Revision as of 18:42, 15 May 2026
Line 35:		Line 35:
	[[Category:Semisynthetic opioids]]		[[Category:Semisynthetic opioids]]
	[[Category:Analgesics]]		[[Category:Analgesics]]
			[[Category:Mu-Opioid Receptor Agonists]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:59Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Opioids]]
			[[Category:Semisynthetic opioids]]
	[[Category:Analgesics]]		[[Category:Analgesics]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:04Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:45Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:48Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Analgesics]]		[[Category:Analgesics]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Oxycodone
+| generic            = Oxycodone
-| brand             = OxyContin
+| brand              = OxyContin
-| classes           = Opioid, Analgesic
+| structure          =
-| mechanism         = Mu-opioid receptor agonist
+| classes            = Opioid, Analgesic
 }}
 [[Category:Analgesics]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Oxycodone
| brand = OxyContin
| classes = Opioid, Analgesic
| mechanism = Mu-opioid receptor agonist
}}
[[Category:Analgesics]]